Neurogene (NGNE) Stock Analysis & Winston Score

Neurogene is a small biotech company that develops gene therapies for rare neurological diseases. Gene therapy works by delivering a corrected copy of a faulty gene directly into a patient's cells, potentially treating the root cause of a disease rather than just the symptoms. The company's main focus is on Rett syndrome, a severe genetic disorder that affects brain development, primarily in young girls.

Neurogene does not yet sell any approved products, so it currently earns no revenue. It funds its research through cash raised from investors, which is typical for early-stage biotech companies. The company operates mainly in the United States and is still in the clinical trial phase, meaning its therapies must prove they are safe and effective before regulators will allow them to be sold. The biggest risk is that clinical trials can fail, and if Neurogene's lead therapy does not succeed, the company would need to raise more money or find a new path forward.

Winston Score History

Growth Profile

For growth stock investors

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

Revenue data limited

EPS Growth

-28.7% YoY

YoY Growth Rate

Earnings declining

Insider Activity

20.7%ownership

→ Flat

Insiders holding steady — not selling despite ability to

Cash Runway

~14 months

$124M cash & investments

Quarterly Free Cash Flow

↓ Burn rate worsening

Adequate runway but may need to raise capital within 2 years

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Gross Margin

N/A

Data not available

Operating Margin

N/A

Data not available

ROCE

-13.5%

Weak — -13.5% return on capital

Negative ROIC means the business is losing money on every dollar invested in it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales YoY

-100.0%

Shrinking sales (-100.0% YoY)

EPS YoY

N/A

—

Data not available

EPS Consistency

0/8 quarters

Earnings rarely grow — volatile business

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Cash Conversion

N/A

—

Data not available

FCF Margin

N/A

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

Debt / Equity

0.04

Conservative — low debt load (0.04)

Interest Cover

N/A

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

P/E Ratio (TTM)

N/M

no trend

Negative earnings — P/E not meaningful

P/E vs Forward

N/A

not available

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.

🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.

Start free trial